Severe bacterial infections in people who inject drugs: the role of injection-related tissue damage

Alexander Hrycko, Pedro Mateu-Gelabert, Courtney Ciervo, Rebecca Linn-Walton, Benjamin Eckhardt, Alexander Hrycko, Pedro Mateu-Gelabert, Courtney Ciervo, Rebecca Linn-Walton, Benjamin Eckhardt

Abstract

Background: In the context of the current U.S. injection drug use epidemic, targeted public health harm reduction strategies have traditionally focused on overdose prevention and reducing transmission of blood-borne viral infections. Severe bacterial infections (SBI) associated with intravenous drug use have been increasing in frequency in the U.S. over the last decade. This qualitative study aims to identify the risk factors associated with SBI in hospitalized individuals with recent injection drug use.

Methods: Qualitative analysis (n = 15) was performed using an in-depth, semi-structured interview of participants admitted to Bellevue Hospital, NYC, with SBI and recent history of injection drug use. Participants were identified through a referral from either the Infectious Diseases or Addition Medicine consultative services. Interviews were transcribed, descriptively coded, and analyzed for key themes.

Results: Participants reported a basic understanding of prevention of blood-borne viral transmission but limited understanding of SBI risk. Participants described engagement in high risk injection behaviors prior to hospitalization with SBI. These practices included polysubstance use, repetitive tissue damage, nonsterile drug diluting water and multipurpose use of water container, lack of hand and skin hygiene, re-use of injection equipment, network sharing, and structural factors leading to an unstable drug injection environment. Qualitative analysis led to the proposal of an Ecosocial understanding of SBI risk, detailing the multi-level interplay between individuals and their social and physical environments in producing risk for negative health outcomes.

Conclusions: Structural factors and injection drug use networks directly impact drug use, injection drug use practices, and harm reduction knowledge, ultimately resulting in tissue damage and inoculation of bacteria into the host and subsequent development of SBI. Effective healthcare and community prevention efforts targeted toward reducing risk of bacterial infections could prevent long-term hospitalizations, decrease health care expenditures, and reduce morbidity and mortality.

Keywords: Injection drug use; Risk factors; Severe bacterial infection; Tissue damage.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Socio-ecological model—multilevel risk factor associated with SBI

References

    1. Hope VD, Ncube F, Parry JV, Hickman M. Healthcare seeking and hospital admissions by people who inject drugs in response to symptoms of injection site infections or injuries in three urban areas of England. Epidemiol Infect. 2015;143(1):120–131. doi: 10.1017/S0950268814000284.
    1. Gordon R, Lowy F. Bacterial infections in drug users. N Engl J Med. 2005;353:1945–1954. doi: 10.1056/NEJMra042823.
    1. Hope V. Neglected infections, real harms: a global scoping of injection-related bacterial infections and responses. In: Harm Reduction International. 2010; p. 89–95.
    1. Gray ME, Rogawski McQuade ET, Scheld WM, Dillingham RA. Rising rates of injection drug use associated infective endocarditis in Virginia with missed opportunities for addiction treatment referral: a retrospective cohort study. BMC Infect Dis. 2018;18(1):1–9. doi: 10.1186/s12879-017-2892-9.
    1. Wurcel AG, Anderson JE, Chui KKH, Skinner S, Knox TA, Snydman DR, et al. Increasing infectious endocarditis admissions among young people who inject drugs. Open Forum Infect Dis. 2016;3(3).
    1. Hartnett KP, Jackson KA, Felsen C, Mcdonald R, Bardossy AC, Gokhale RH, et al. Morbidity and mortality weekly report bacterial and fungal infections in persons who inject drugs-western New York, 2017.
    1. Collier MG, Doshani M, Asher A. Using population based hospitalization data to monitor increases in conditions causing morbidity among persons who inject drugs. J Community Health. 2018;43(3):598–603. doi: 10.1007/s10900-017-0458-9.
    1. Bates MC, Annie F, Jha A, Kerns F. Increasing incidence of IV-drug use associated endocarditis in southern West Virginia and potential economic impact. Clin Cardiol. 2019;42(4):432–437. doi: 10.1002/clc.23162.
    1. Kadri AN, Wilner B, Hernandez AV, Nakhoul G, Chahine J, Griffin B, et al. Geographic trends, patient characteristics, and outcomes of infective endocarditis associated with drug abuse in the united states from 2002 to 2016. J Am Heart Assoc. 2019;8(19):1–10. doi: 10.1161/JAHA.119.012969.
    1. Fleischauer AT, Ruhl L, Rhea S, Barnes E. Hospitalizations for endocarditis and associated health care costs among persons with diagnosed drug dependence—North Carolina, 2010–2015. MMWR Morb Mortal Wkly Rep. 2017;66(22):569. doi: 10.15585/mmwr.mm6622a1.
    1. Rudasill SE, Sanaiha Y, Mardock AL, Khoury H, Xing H, Antonios JW, et al. Clinical outcomes of infective endocarditis in injection drug users. J Am Coll Cardiol. 2019;73(5):559–570. doi: 10.1016/j.jacc.2018.10.082.
    1. Magsino K, Sanjanwala R, Hiebert B, Rothney J, Manji R, Arora R, et al. Treatment outcomes for right-sided endocarditis in intravenous drug users: a systematic review and analysis of outcomes in a tertiary centre. Thorac Cardiovasc Surg. 2018;66(7):552–562. doi: 10.1055/s-0037-1618578.
    1. Shrestha NK, Jue J, Hussain ST, Jerry JM, Pettersson GB, Menon V, et al. Injection drug use and outcomes after surgical intervention for infective endocarditis. Ann Thorac Surg. 2015;100(3):875–882. doi: 10.1016/j.athoracsur.2015.03.019.
    1. Morita Y, Haruna T, Haruna Y, Nakane E, Yamaji Y, Hayashi H, et al. Thirty-day readmission after infective endocarditis: analysis from a nationwide readmission database. J Am Heart Assoc. 2019;8(9):e011598. doi: 10.1161/JAHA.118.011598.
    1. Aspinall EJ, Nambiar D, Goldberg DJ, Hickman M, Weir A, Van Velzen E, et al. Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. Int J Epidemiol. 2014;43(1):235–248. doi: 10.1093/ije/dyt243.
    1. Schulte M, Hser Y, Saxon A, Evans E, Li L, Huang D, et al. Risk factors associated with HCV among opioid-dependent patients in a multisite study. J Community Health. 2015;40(5):940–947. doi: 10.1007/s10900-015-0016-2.
    1. Villano S, Vlahov D, Nelson KE, Lyles CM, Cohn S, Thomas DL. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol. 1997;35(12):3274–7. doi: 10.1128/jcm.35.12.3274-3277.1997.
    1. Hahn JA, Page-Shafer K, Lum PJ, Ochoa K, Moss AR. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology. 2001;34(1):180–7. doi: 10.1053/jhep.2001.25759.
    1. Eckhardt B, Winkelstein ER, Shu MA, Carden MR, McKnight C, Des Jarlais DC, et al. Risk factors for hepatitis C seropositivity among young people who inject drugs in New York City: implications for prevention. PLoS ONE. 2017;12(5):1–16. doi: 10.1371/journal.pone.0177341.
    1. See I, Gokhale RH, Geller A, Lovegrove M, Schranz A, Fleischauer A, et al. National public health burden estimates of endocarditis and skin and soft-tissue infections related to injection drug use: a review. J Infect Dis. 2020;222(Suppl_5):S429–36. doi: 10.1093/infdis/jiaa149.
    1. Leung NS, Padgett P, Robinson DA, Brown EL. Prevalence and behavioural risk factors of Staphylococcus aureus nasal colonization in community-based injection drug users. Epidemiol Infect. 2015;143(11):2430–2439. doi: 10.1017/S0950268814003227.
    1. Fleisch F, Zbinden R, Vanoli C, Ruef C. Epidemic spread of a single clone of methicillin-resistant Staphylococcus aureus among injection drug users in Zurich, Switzerland. Clin Infect Dis. 2001;32(4):581–586. doi: 10.1086/318716.
    1. Packer S, Pichon B, Thompson S, Neale J, Njoroge J, Kwiatkowska RM, et al. Clonal expansion of community-associated meticillin-resistant staphylococcus aureus (MRSA) in people who inject drugs (PWID): prevalence, risk factors and molecular epidemiology, Bristol, United Kingdom, 2012 to 2017. Eurosurveillance. 2019;24(13):1800124. doi: 10.2807/1560-7917.ES.2019.24.13.1800124.
    1. Jackson KA, Bohm MK, Brooks JT, Asher A, Nadle J, Bamberg WM, Petit S, Ray SM, Harrison LH, Lynfield R, Dumyati G. Invasive methicillin-resistant Staphylococcus aureus infections among persons who inject drugs—six sites, 2005–2016. Morb Mortal Wkly Rep. 2018;67:625. doi: 10.15585/mmwr.mm6722a2.
    1. Phillips KT, Stein MD. Risk practices associated with bacterial infections among injection drug users in Denver, Colorado. Am J Drug Alcohol Abuse. 2010;36(2):92–97. doi: 10.3109/00952991003592311.
    1. Phillips KT, Anderson BJ, Herman DS, Liebschutz JM, Stein MD. Risk factors associated with skin and soft tissue infections among hospitalized people who inject drugs. J Addict Med. 2017;11(6):461–467. doi: 10.1097/ADM.0000000000000346.
    1. Islam S, Piggott DA, Moriggia A, Astemborski J, Mehta SH, Thomas DL, et al. Reducing injection intensity is associated with decreased risk for invasive bacterial infection among high-frequency injection drug users. Harm Reduct J. 2019;16(1):1–9. doi: 10.1186/s12954-019-0312-8.
    1. Harris M, Scott J, Wright T, Brathwaite R, Ciccarone D, Hope V. Injecting-related health harms and overuse of acidifiers among people who inject heroin and crack cocaine in London: a mixed-methods study. Harm Reduct J. 2019;16(1):60. doi: 10.1186/s12954-019-0330-6.
    1. Harris M, Scott J, Hope V, Wright T, McGowan C, Ciccarone D. Navigating environmental constraints to injection preparation: the use of saliva and other alternatives to sterile water among unstably housed PWID in London. Harm Reduct J. 2020;17(1):24. doi: 10.1186/s12954-020-00369-0.
    1. Robertson R, Broers B, Harris M. Injecting drug use, the skin and vasculature. Addiction. 2021;116(7):1914–1924. doi: 10.1111/add.15283.
    1. Rhodes T. Risk environments and drug harms: a social science for harm reduction approach. Int J Drug Policy. 2009;20:193–201. doi: 10.1016/j.drugpo.2008.10.003.
    1. Collins AB, Boyd J, Cooper HLF, McNeil R. The intersectional risk environment of people who use drugs. Soc Sci Med. 2019;234:112384. doi: 10.1016/j.socscimed.2019.112384.
    1. Kenney SR, Anderson BJ, Conti MT, Bailey GL, Stein MD. Expected and actual fentanyl exposure among persons seeking opioid withdrawal management. J Subst Abuse Treat. 2018;86:65–69. doi: 10.1016/j.jsat.2018.01.005.
    1. Daniulaityte R, Juhascik MP, Strayer KE, Sizemore IE, Harshbarger KE, Antonides HM, et al. Overdose deaths related to fentanyl and its analogs—Ohio, January–February 2017. MMWR Morb Mortal Wkly Rep. 2017;66(34):904–908. doi: 10.15585/mmwr.mm6634a3.
    1. Fiorentin TR, Krotulski AJ, Martin DM, Browne T, Triplett J, Conti T, et al. Detection of cutting agents in drug-positive seized exhibits within the United States. J Forensic Sci. 2019;64(3):888–896. doi: 10.1111/1556-4029.13968.
    1. Lambdin BH, Bluthenthal RN, Zibbell JE, Wenger L, Simpson K, Kral AH. Associations between perceived illicit fentanyl use and infectious disease risks among people who inject drugs. Int J Drug Policy. 2019;74:299–304. doi: 10.1016/j.drugpo.2019.10.004.
    1. Mateu-Gelabert P, Sandoval M, Meylakhs P, Wendel T, Friedman SR. Strategies to avoid opiate withdrawal: implications for HCV and HIV risks. Int J Drug Policy. 2010;21(3):179–185. doi: 10.1016/j.drugpo.2009.08.007.
    1. Murphy EL, DeVita D, Liu H, Vittinghoff E, Leung P, Ciccarone DH, et al. Risk factors for skin and soft-tissue abscesses among injection drug users: a case-control study. Clin Infect Dis. 2001;33(1):35–40. doi: 10.1086/320879.
    1. Spijkerman IJB, Van Ameijden EJC, Mientjes GHC, Coutinho RA, Van Den Hoek A. Human immunodeficiency virus infection and other risk factors for skin abscesses and endocarditis among injection drug users. J Clin Epidemiol. 1996;49(10):1149–1154. doi: 10.1016/0895-4356(96)00180-1.
    1. Delaney KA. Endocarditis in the emergency department. Ann Emerg Med. 1991;20(4):405–414. doi: 10.1016/S0196-0644(05)81663-4.
    1. Frontera JA, Gradon JD. Right-side endocarditis in injection drug users: review of proposed mechanisms of pathogenesis. Clin Infect Dis. 2000;30(2):374–379. doi: 10.1086/313664.
    1. Brett MM, Hood J, Brazier JS, Duerden BI, Hahné SJM. Soft tissue infections caused by spore-forming bacteria in injecting drug users in the United Kingdom. Epidemiol Infect. 2005;133(4):575–582. doi: 10.1017/S0950268805003845.
    1. Krieger N. Embodiment: a conceptual glossary for epidemiology. J Epidemiol Community Health. 2005;59(5):350–355. doi: 10.1136/jech.2004.024562.
    1. Krieger N. Epidemiology and the web of causation: Has anyone seen the spider? Soc Sci Med. 1994;39(7):887–903. doi: 10.1016/0277-9536(94)90202-X.
    1. Hope V, Kimber J, Vickerman P, Hickman M, Ncube F. Frequency, factors and costs associated with injection site infections: findings from a national multi-site survey of injecting drug users in England. BMC Infect Dis. 2008;8:1–9. doi: 10.1186/1471-2334-8-120.
    1. Summers PJ, Struve IA, Wilkes MS, Rees VW. Injection-site vein loss and soft tissue abscesses associated with black tar heroin injection: a cross-sectional study of two distinct populations in USA. Int J Drug Policy. 2017;39:21–27. doi: 10.1016/j.drugpo.2016.08.006.
    1. Gilbert AR, Hellman JL, Wilkes MS, Rees VW, Summers PJ. Self-care habits among people who inject drugs with skin and soft tissue infections: a qualitative analysis. Harm Reduct J. 2019;16(1):69. doi: 10.1186/s12954-019-0345-z.
    1. Monteiro J, Phillips KT, Herman DS, Stewart C, Keosaian J, Anderson BJ, et al. Self-treatment of skin infections by people who inject drugs. Drug Alcohol Depend. 2020;206:107695. doi: 10.1016/j.drugalcdep.2019.107695.
    1. Vermandere M, Aertgeerts B, Agoritsas T, Liu C, Burgers J, Merglen A, et al. Antibiotics after incision and drainage for uncomplicated skin abscesses: a clinical practice guideline. BMJ. 2018;360:k243. doi: 10.1136/bmj.k243.
    1. McNeil R, Small W, Wood E, Kerr T. Hospitals as a “risk environment”: an ethno-epidemiological study of voluntary and involuntary discharge from hospital against medical advice among people who inject drugs. Soc Sci Med. 2014;105:59–66. doi: 10.1016/j.socscimed.2014.01.010.
    1. U.S. Department of Health and Human Services. Syringe Services Programs | . 2020;
    1. The Global Fund. Harm reduction for people who use drugs. 2020.
    1. Newman A, Mays JC. Nation’s First Supervised Drug-Injection Sites Open in New York. New York Times. 2021;

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅